SYN - Synthetic Biologics stock rises as oral drug SYN-020 shows safety in early-stage study

Synthetic Biologics (NYSE:SYN) said its oral drug SYN-020 was seen to be well tolerated across all doses in healthy people in an early stage study. The company reported data from a phase 1 multiple ascending dose (MAD) trial of SYN-020, a recombinant bovine intestinal alkaline phosphatase (IAP) formulated for oral delivery. Synthetic Biologics (SYN) added that it is continuing to evaluate potential lead uses of SYN-020, which may include  celiac disease, nonalcoholic fatty liver disease, radiation enteropathy, and metabolic and inflammatory disorders associated with aging. The phase 1 MAD study enrolled 32 healthy adult volunteers into four groups with SYN-020 administered orally in doses ranging from 5 mg to 75 mg twice daily for 14 days with a follow-up evaluation at day 35. Each group included six people who received SYN-020 and two who received placebo. The company said that preliminary data showed that SYN-020 maintained a favorable safety profile and

For further details see:

Synthetic Biologics stock rises as oral drug SYN-020 shows safety in early-stage study